Next Generation CAR & T Cell Therapies is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jonathan Bramson
Co-Founder & CSO at Triumvira Immunologics, Inc.


Jonathan Bramson, PhD, is a Professor in the Department of Pathology and Molecular Medicine and the Vice Dean, Research for the Faculty of Health Sciences. He holds a Tier I Canada Research Chair in Translational Cancer Immunology and the John Bienestock Chair in Molecular Medicine. The Bramson lab is focused on developing methods to direct cancer patients’ immune systems to attack their tumors. Currently, the lab is using synthetic biology methods to direct T cells against discrete tumor targets. Of note, the Bramson lab has created a novel chimeric receptor, known as the T cell antigen coupling (TAC) receptor, that displays enhanced anti-tumor activity and reduced toxicity relative to conventional CARs in pre-clinical models. Dr. Bramson co-founded Triumvira Immunologics in 2015 to commercialize the TAC technology and currently serves as the company’s CSO.

Jonathan Bramson's Network

Agenda Sessions

  • Triumvira Immunologics Case Study

    , 4:00pm